Index - P/E - EPS (ttm) -3.27 Insider Own 0.83% Shs Outstand 12.19M Perf Week -2.40%
Market Cap 7.70M Forward P/E - EPS next Y - Insider Trans -98.41% Shs Float 12.08M Perf Month 7.03%
Enterprise Value 32.45M PEG - EPS next Q - Inst Own 4.17% Short Float 2.62% Perf Quarter 29.94%
Income -38.47M P/S 769.80 EPS this Y - Inst Trans 30.96% Short Ratio 0.90 Perf Half Y -46.49%
Sales 0.01M P/B - EPS next Y - ROA -121.80% Short Interest 0.32M Perf YTD -56.45%
Book/sh -0.85 P/C 12.42 EPS next 5Y - ROE -590.45% 52W High 6.17 -89.76% Perf Year -
Cash/sh 0.05 P/FCF - EPS past 3/5Y -166.64% -153.63% ROIC - 52W Low 0.36 74.40% Perf 3Y -
Dividend Est. - EV/EBITDA - Sales past 3/5Y - - Gross Margin -16214.29% Volatility 10.62% 8.75% Perf 5Y -
Dividend TTM - EV/Sales 3244.80 EPS Y/Y TTM -758.39% Oper. Margin -59500.00% ATR (14) 0.06 Perf 10Y -
Dividend Ex-Date - Quick Ratio 0.04 Sales Y/Y TTM - Profit Margin -549628.57% RSI (14) 51.16 Recom -
Dividend Gr. 3/5Y - - Current Ratio 0.06 EPS Q/Q -1224.30% SMA20 1.99% Beta 5.84 Target Price -
Payout - Debt/Eq - Sales Q/Q - SMA50 1.19% Rel Volume 0.45 Prev Close 0.68
Employees 2 LT Debt/Eq - Earnings - SMA200 -46.34% Avg Volume 352.18K Price 0.63
IPO Sep 16, 2024 Option/Short No / Yes EPS/Sales Surpr. - - Trades
Volume 157,413 Change -7.38%
Aug-18-25 08:30AM
Jun-23-25 07:52AM
Mar-21-25 02:38PM
Feb-26-25 08:30AM
08:30AM
04:30PM
Loading…
Jan-23-25 04:30PM
Nov-19-24 08:00AM
Nov-18-24 07:00AM
Nov-11-24 07:30AM
Oct-15-24 06:00AM
Oct-07-24 08:30AM
Sep-26-24 08:30AM
Sep-23-24 08:00AM
Sep-17-24 11:29AM
Sep-16-24 04:26PM
10:24AM
Loading…
10:24AM
Impact BioMedical, Inc. is a holding company, which engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. The firm focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. It is also involved in developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. The company was founded on October 16, 2018 and is headquartered in Houston, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
DSS, INC. 10% Owner May 22 '25 Sale 0.55 115,600 63,476 45,400 May 27 04:35 PM DSS, INC. 10% Owner May 27 '25 Sale 0.54 45,400 24,530 0 May 27 04:35 PM DSS, INC. 10% Owner Apr 04 '25 Sale 0.95 890,800 845,013 161,100 Apr 07 09:59 PM Chan Heng Fai Ambrose Director Apr 03 '25 Sale 0.49 351,555 174,020 0 Apr 07 05:18 PM Chan Heng Fai Ambrose Director Apr 02 '25 Sale 0.60 884,776 533,636 351,555 Apr 04 05:15 PM Chan Heng Fai Ambrose Director Apr 03 '25 Sale 0.67 624,917 416,484 0 Apr 04 05:15 PM Chan Heng Fai Ambrose Director Apr 04 '25 Sale 0.96 180,000 172,800 0 Apr 04 05:15 PM Chan Heng Fai Ambrose Director Apr 01 '25 Sale 1.17 2,226,918 2,604,421 734,058 Apr 02 09:01 PM Chan Heng Fai Ambrose Director Mar 31 '25 Sale 1.03 300,000 308,400 1,253,904 Apr 02 09:01 PM DSS, INC. 10% Owner Mar 21 '25 Sale 3.30 499,800 1,649,540 0 Mar 28 05:25 PM DSS, INC. 10% Owner Mar 26 '25 Sale 3.13 58,139 182,134 1,099,481 Mar 28 05:25 PM DSS, INC. 10% Owner Mar 27 '25 Sale 2.50 47,681 119,255 1,051,800 Mar 28 05:25 PM DSS, INC. 10% Owner Mar 20 '25 Buy 1.55 200 310 53,280 Mar 24 08:00 PM DSS, INC. 10% Owner Mar 20 '25 Sale 4.68 53,280 249,350 0 Mar 24 08:00 PM DSS, INC. 10% Owner Dec 02 '24 Sale 2.90 20 58 53,080 Mar 24 08:00 PM Heuszel Frank D Chief Executive Officer Dec 05 '24 Buy 2.26 500 1,129 97,344 Dec 09 04:05 PM Heuszel Frank D Chief Executive Officer Nov 27 '24 Buy 2.61 500 1,305 96,844 Dec 03 09:51 PM Heuszel Frank D Chief Executive Officer Nov 26 '24 Buy 2.61 1,050 2,739 96,344 Dec 03 09:49 PM DSS, INC. 10% Owner Nov 18 '24 Sale 3.02 5,000 15,085 53,100 Nov 22 04:33 PM DSS, INC. 10% Owner Nov 12 '24 Sale 2.76 500 1,378 58,300 Nov 22 04:33 PM DSS, INC. 10% Owner Nov 13 '24 Sale 2.80 200 560 58,100 Nov 22 04:33 PM
